FIELD: medicine.
SUBSTANCE: invention can be used to treat a subject suffering from acute myeloid leukemia (AML), mediated by FMS-like tyrosine kinase 3 (Flt3) gene with internal tandem duplications (ITD) mutation. The specified subject receives an effective number of PLX3397 compound or its salts.
EFFECT: invention provides treatment of patients with AML due to effective inhibition of tumour cell proliferation, activated by a mutant FLT3.
10 cl, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS FOR USE OF SAID COMPOUNDS AND METHODS | 2008 |
|
RU2487121C2 |
| PYROLLO [2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2012 |
|
RU2629999C2 |
| PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2565071C2 |
| COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS FOR THEIR USE | 2013 |
|
RU2666146C2 |
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2014 |
|
RU2680100C9 |
| 1,3-DIARYL-SUBSTITUTED UREAS AS KINASE ACTIVITY MODULATORS | 2006 |
|
RU2402544C2 |
| COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USE THEREOF | 2007 |
|
RU2452738C2 |
| DERIVATIVES OF AMINOINDAZOLS AND THEIR APPLICATION AS KINASES INHIBITORS | 2003 |
|
RU2339624C2 |
| METHOD FOR TREATMENT OF STATES CAUSED BY p38 KINASES AND PYRROLOTRIAZINE COMPOUNDS USED AS KINASE INHIBITORS | 2001 |
|
RU2316556C2 |
| PYRROLO[2,3-B]PYRIDINE DERIVATIVE AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2418800C2 |
